Supply of interferon beta 1-A and other drugs
Original notice title
Suministro de medicamentos principios activos: INTERFERON BETA 1-A, CANNABINOL-RONABINOL Y AVELUMAB, dispensados en el Hospital Universitario dependiente del INGESA para los pacientes de la Gerencia de Atención Sanitaria de Melilla.
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
Full procurement documents were not analyzed; critical terms, conditions, and specifications may be missed.
Award criteria for LOT-0002 vary between structured data (quality only) and XML (70% price / 30% quality). This could a...
Submission deadline in 7 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- EUR 690.9k estimated value
- Supplies contract
- 3 lots
- Duration 1 YEAR
- Supply of three specific pharmaceutical active ingredients: Interferon Beta 1-A, Cannabino-Dronabinol, and Avelumab.
- Dispensing at the University Hospital of Melilla under the Gerencia de Atención Sanitaria de Melilla (INGESA).
Show full summary
Open procedure for the supply of three pharmaceutical active ingredients (Interferon Beta 1-A, Cannabino-Dronabinol, and Avelumab) to the University Hospital of Melilla, Spain. The contract is divided into three lots with a total estimated value of €690,934.65. Submission deadline is July 1, 2026. Only Spanish language submissions accepted. Documentation beyond the notice was not analyzed.
Risks
Full procurement documents were not analyzed; critical terms, conditions, and specifications may be missed.
Award criteria for LOT-0002 vary between structured data (quality only) and XML (70% price / 30% quality). This could a...
Submission deadline in 7 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Administrative
- Electronic submission via the provided platform
- Submissions in Spanish only
- Tenderers must submit documentation for price and quality criteria
Award Criteria
Lot 1
Lot 2
Lot 3
Buyer
Name
Gerencia de Atención Sanitaria de Melilla - Instituto Nacional de Gestión Sanitaria
Location
Melilla, ESP
Website
Buyer profile
Identifier
10000440056201
Lots (3)
LOT-0001
Medicamento Interferon BETA 1-A
Supply of Interferon Beta 1-A medicinal product.
EUR 532.9k
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
MEDICAMENTO INTERFERON BETA 1-A
LOT-0002
Medicamento Cannabino-Dronabinol
Supply of Cannabino-Dronabinol medicinal product.
EUR 8.9k
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Medicamento Cannabino-Dronabinol
LOT-0003
Medicamento Avelumab
Supply of Avelumab medicinal product.
EUR 149.1k
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Medicamento Avelumab
Procurement Details
- Publication date
- 01 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Spanish
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 378009-2026
- Source notice ID
- 7648a78d-e923-412f-9101-1a5fe59ea1d4
Documents (1)
Similar tenders
Denmark – Pharmaceutical products – Amgros 2027 1.1051.b
Poland – Pharmaceutical products – Dostawa produktów leczniczych do SPZZOZ w Wyszkowie
Romania – Pharmaceutical products – MEDICAMENTE - PRODUSE FARMACEUTICE
Denmark – Pharmaceutical products – Amgros 2027 1.1052.b
Latvia – Pharmaceutical products – Par reģistrēto un nereģistrēto medikamentu piegādi Elektronisko iepirkumu sistēmas dalībniekiem
Spain – Pharmaceutical products – Suministro de Aflibercept (DOE) Intravítreo 40 mg/ml
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
Full procurement documents were not analyzed; critical terms, conditions, and specifications may be missed.
Award criteria for LOT-0002 vary between structured data (quality only) and XML (70% price / 30% quality). This could a...
Submission deadline in 7 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications